Clinical trial

TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer

NCT01354522

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2011-05-01

PhasePHASE3

Study timeline

Study start (actual)2011-05-01Date precision: month

Registry last updated2025-06-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

Docetaxel, Doxorubicin, CyclophosphamideDRUG

Docetaxel, Cyclophosphamide, CapecitabineDRUG

Sponsors & collaborators

Peking Union Medical College Hospitallead sponsor

Mapped research locations

BeijingBeijing Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01354522 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.